E-viri
Recenzirano
Odprti dostop
-
Estepp, Jeremie H.; Kalpatthi, Ram; Woods, Gerald; Trompeter, Sara; Liem, Robert I.; Sims, Kacie; Inati, Adlette; Inusa, Baba P. D.; Campbell, Andrew; Piccone, Connie; Abboud, Miguel R.; Smith‐Whitley, Kim; Dixon, Sandra; Tonda, Margaret; Washington, Carla; Griffin, Noelle M.; Brown, Clark
Pediatric blood & cancer, August 2022, Letnik: 69, Številka: 8Journal Article
Background Sickle cell disease (SCD) is a devastating, multisystemic disorder that affects millions of people worldwide. The earliest clinical manifestations of SCD can affect infants as young as 6 months of age, and pediatric patients are at risk for acute and life‐threatening complications. Early intervention with treatments that target the underlying pathophysiological mechanism of SCD, sickle hemoglobin (HbS) polymerization, are expected to slow disease progression and circumvent disease‐associated morbidity and mortality. Procedure The HOPE‐KIDS 1 trial (NCT02850406) is an ongoing four‐part, phase 2a, open‐label, single‐ and multiple‐dose study to evaluate the pharmacokinetics, efficacy, and safety of voxelotor—a first‐in‐class HbS polymerization inhibitor—in patients aged 6 months to 17 years with SCD. Initial findings from a cohort of 45 patients aged 4 to 11 years who received voxelotor treatment for up to 48 weeks are reported. Results Hemoglobin (Hb) response, defined as a >1.0 g/dl increase from baseline, was achieved at week 24 by 47% (n = 16/34) of patients with Hb measurements at baseline and week 24. At week 24, 35% (n = 12/34) and 21% (n = 7/34) of patients had a >1.5 g/dl increase and a >2.0 g/dl increase from baseline in Hb concentration, respectively. Concurrent improvements in hemolytic markers were observed. Voxelotor was well tolerated in this young cohort, with no newly emerging safety signals. Conclusions Based on its mechanism as an HbS polymerization inhibitor, voxelotor improves Hb levels and markers of hemolysis and has the potential to mitigate SCD‐related complications; these results support its use in patients aged ≥4 years.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.